Safety and Efficacy of Insulins in Critically Ill Patients Receiving Continuous Enteral Nutrition.
Endocr Pract
; 30(4): 367-371, 2024 Apr.
Article
en En
| MEDLINE
| ID: mdl-38307456
ABSTRACT
OBJECTIVE:
There is a relative lack of consensus regarding the optimal management of hyperglycemia in patients receiving continuous enteral nutrition (EN), with or without a diagnosis of diabetes.METHODS:
This retrospective study examined 475 patients (303 with known diabetes) hospitalized in critical care setting units in 2019 in a single center who received continuous EN. Rates of hypoglycemia, hyperglycemia, and glucose levels within the target range (70-180 mg/dL) were compared between patients with and without diabetes, and among patients treated with intermediate-acting (IA) biphasic neutral protamine Hagedorn 70/30, long-acting (LA) insulin, or rapid-acting insulin only.RESULTS:
Among those with type 2 diabetes mellitus, IA and LA insulin regimens were associated with a significantly higher proportion of patient-days in the target glucose range and fewer hyperglycemic days. Level 1 (<70 mg/dL) and level 2 (<54 mg/dL) hypoglycemia occurred rarely, and there were no significant differences in level 2 hypoglycemia frequency across the different insulin regimens.CONCLUSION:
Administration of IA and LA insulin can be safe and effective for those receiving insulin doses for EN-related hyperglycemia.Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Diabetes Mellitus Tipo 2
/
Hiperglucemia
/
Hipoglucemia
Tipo de estudio:
Observational_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Año:
2024
Tipo del documento:
Article